Pharma & biotech
Obesity drugs are driving record growth: Lilly’s Q3 revenue rose 39%, with volume up 53% even as realised prices fell 15%. Around $300B of industry revenue loses patent protection by 2030, which is pushing companies into M&A ($130B in H1 2026 alone). Washington now effectively sets prices: 26 drugmakers have signed most-favoured-nation pricing deals, and the rest face 100% tariffs on patented imports. Biotech is recovering, with the XBI index up 27% year to date and the IPO window open again.

The first slides, as they appear in the reader.




No PDF to download or forward.
How to read it.
Starter
Not included
Qubo Research is for subscribers, from Pulse.
Pulse · Edge
Apex only
Sector overviews and ideas are part of the Apex library.
Apex
Library included
Every report, every edition and the archives. 5 custom reports a month.
Editions:Q4 2026Follow the series in the Terminal to get the next one.
Read it next to the live PHARMA-BIOTECH chart.
Open the report in the Terminal: price, news and why it moves, on the same screen.
General research, the same for every reader: it does not take anyone’s situation into account and does not recommend buying, selling or holding any asset. No price targets. May contain errors.